Synektik, a manufacturer of radiopharmaceuticals and distributor of medical equipment, recorded a 94% increase in sales revenue in Q4 2018. The good financial results are largely due to the sale of medical robots.
94% increase in Synektik’s revenues
In Q4 2018 (first quarter of Sinektik’s financial year 2018/2019), the company generated sales revenues of nearly PLN 66m which constituted an increase by 94% year on year. In the medical and IT equipment segment, revenues increased by over 100% to PLN 60.5m. At the same time, EBITDA amounted to PLN 11.9m as compared to PLN 4.7m a year earlier. Of which, in the fourth quarter of 2018, PLN 11.7m EBITDA was generated by the medical and IT equipment segment.
The company informed that the expansion in the segment of supplies of therapy equipment, including mainly the da Vinci robot system, determined the jump in revenue growth. In Q4 2018. Synektik delivered da Vinci to two public hospitals in Poznan and Bialystok and a private Medicover Hospital in Warsaw. This year, da Vinci was also delivered to Szpital na Klinach in Cracow. The company is the exclusive distributor of Intuitive Surgical in Poland.
At least four medical robots by the end of 2019
According to Puls Biznesu, Synektik plans to sell at least four da Vinci robot systems in Poland this year. Sales of one device to revenues of about PLN 10m (depending on configuration). In addition, there are revenues from one-off instruments and maintenance services.
The company estimates that within the next 3-4 years approximately 20 da Vinci systems may operate in Poland.
Not only da Vinci
Synektik does not intend to limit itself only to the distribution of da Vinci systems. In May, the company launched the Apoteca chemo robot, which is used for automatic preparation of intravenous drugs used in anticancer therapies. It is manufactured by the Italian concern Loccioni, and Synektik has exclusive distribution rights to the Polish market.
Synektik will also distribute in Poland further medical robots of Intuitive Surgical. According to Puls Biznesu, the American concern has obtained FDA approval for the introduction of the Ion robot, intended for lung tumor biopsy. The company will also introduce the Vinci SP system, which will be used in minimally invasive procedures in the abdominal cavity and laryngology.